Vitamin D insufficiency and deficiency with stages of chronic kidney disease in an Asian population by Bancha Satirapoj et al.
Satirapoj et al. BMC Nephrology 2013, 14:206
http://www.biomedcentral.com/1471-2369/14/206RESEARCH ARTICLE Open AccessVitamin D insufficiency and deficiency with stages
of chronic kidney disease in an Asian population
Bancha Satirapoj*, Pokkrong Limwannata, Amnart Chaiprasert, Ouppatham Supasyndh and Panbuppa ChoovichianAbstract
Background: Vitamin D insufficiency is associated with proteinuria and could be a risk factor for end-stage renal
disease (ESRD). However, few studies have examined the significance of vitamin D insufficiency as a contributing
factor for the development of ESRD in the Asian chronic kidney disease (CKD) population.
Methods: Authors examined the relationship between vitamin D status and the staging of CKD using data from an
outpatient clinic-based screening in 2,895 Thai CKD patients. Serum levels of 25-hydroxyvitamin D were analyzed
according to CKD stages. Vitamin D deficiency and insufficiency were defined as a serum 25-hydroxyvitamin D
concentration < 10 ng/mL and 10–30 ng/mL, respectively.
Results: The mean (SD) 25-hydroxyvitamin D levels were significantly lower according to severity of renal
impairment (CKD stage 3a: 27.84±14.03 ng/mL, CKD stage 3b: 25.86±11.14 ng/mL, CKD stage 4: 24.09±11.65 and
CKD stage 5: 20.82±9.86 ng/mL, p<0.001). The prevalence of vitamin D deficiency/insufficiency was from CKD stage
3a, 3b, 4 to 5, 66.6%, 70.9%, 74.6%, and 84.7% (p<0.001). The odds ratio (95% CI) of vitamin D insufficiency/
deficiency (serum 25-hydroxyvitamin D ≤ 30 ng/mL) and vitamin D deficiency (serum 25-hydroxyvitamin D < 10
ng/mL) for developing ESRD, after adjustment for age, gender, hemoglobin, serum albumin, calcium, phosphate
and alkaline phosphatase were 2.19 (95% CI 1.07 to 4.48) and 16.76 (95% CI 4.89 to 57.49), respectively.
Conclusion: This study demonstrates that 25-hydroxyvitamin D insufficiency and deficiency are more common and
associated with the level of kidney function in the Thai CKD population especially advanced stage of CKD.
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Presence of vitamin D deficiency, both in the general
population and in patients with chronic kidney disease
(CKD), is based mainly on the effects of vitamin D on
calcium homeostasis and bone health. Bone disorders,
mineral abnormalities and vascular calcification in indi-
viduals with moderate to advanced CKD seem to be re-
lated to a progressive deficiency of active vitamin D and
worsening secondary hyperparathyroidism. Serum levels
of 25-hydroxyvitamin D are also inversely associated
with serum PTH level both in patients with CKD [1]
and in those without this disease [2]. Serum 25-
hydroxyvitamin D is also an inverse predictor of disease
progression and death in patients with CKD [3,4].* Correspondence: satirapoj@yahoo.com
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reproduction in any medium, provided the orA high prevalence of mineral metabolite abnormalities
and vitamin D insufficiency or deficiency occurs in a
large number of US adults with CKD and undergoing
dialysis [5,6]. Recent observations have indicated that
serum 25-hydroxyvitamin D is significantly lower in par-
ticipants with a severe decrease in estimated glomerular
filtration rate (GFR) compared with those with normal
kidney function [7]. Therefore, the recent Kidney Disease
Outcomes Quality Initiative (KDOQI) Clinical Practice
Guidelines for Bone Mineral Metabolism and Disease in
Chronic Kidney Disease recommend the measurements of
25-hydroxyvitamin D levels in patients with CKD not yet
on dialysis.
Currently, clinical evidence supporting a strong link
between vitamin D insufficiency or deficiency and the
risk of CKD, CVD and infectious diseases both in the
general population and in patients with CKD, is rapidly
accumulating [8-11]. Previous reports come from smallal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sociation between vitamin D status and kidney function
in the CKD population [12,13]. In addition, a higher
serum vitamin D level is expected in inhabitants of the
tropics vis-a-vis inhabitants of nontropical regions, due
to greater sun exposure and increased production of
vitamin D. Thai patients with CKD are more likely to
have high sun exposure; however, no clinical study in
the Thai CKD population has been performed to support
this assertion. Therefore, we determined the relationship
between hypovitaminosis D and CKD stages in this
population.
Methods
A cross-sectional study was carried out in 2,895 CKD
patients who followed up at the outpatient clinic of
Phramongkutklao Hospital between January 1, 2010 and
December 31, 2012 and had their 25-hydroxyvitamin D
level assessed. All subjects did not use vitamin D supple-
ment before being enrolled in the study. A detailed med-
ical history was collected by reviewing medical records
of the hospitals of all patients. This study was approved
by our hospital Human Research Ethics Committee. All
subjects gave written informed consent. For the pur-
poses of the present study, we excluded participants with
estimated GFR > 60 mL/min/1.73 m2 or those missing
serum creatinine information.
All biochemical analyses of blood samples were
conducted at the Phramongkutklao Hospital Laboratory.
Serum creatinine was analyzed using the enzymatic
method, calibrated to be traceable to isotope dilution mass
spectrometry. An estimate of the GFR was obtained by
the 2009 CKD-EPI creatinine equation [14]. Irrespective
of the presence or absence of proteinuria, CKD was de-
fined as a GFR of < 60 mL/min per 1.73 m2. The CKD
subjects were categorized by the KDIGO Clinical Practice
Guidelines for Chronic Kidney Disease in four stages:
CKD stage 3a (45–59 mL/min/1.73 m2), CKD stage 3b
(30–44 mL/min/1.73 m2), CKD stage 4 (15–29 mL/min/
1.73 m2) and CKD stage 5 (<15 mL/min/1.73 m2).
Serum 25-hydroxyvitamin D concentrations, as a reliable
measure of overall vitamin D status, were measured by
electrochemiluminescence immunoassay (ECLIA) on a
Roche Elecsys 10100/201 system (Roche Diagnosis Elecsys);
intra- and interassay coefficients of variation were below
5% and 9%, respectively. A 25-hydroxyvitamin D deficiency
was defined as having levels less than 10 ng/mL, and insuf-
ficiency, as having levels of 10 to 30 ng/mL.
Statistical analysis
Descriptive data were examined for all variables. For
continuous variables, results are presented as mean±SD.
Statistical differences in variables were compared using
one-way analysis of variance (ANOVA) and unpairedStudent’s t-test for normally distributed variables and
Kruskal-Wallis Test for non-normally distributed vari-
ables. Categorical variables were recorded as frequency
counts, and intergroup comparisons were analyzed by
chi-squared test. Associations between vitamin D status
and CKD stage 5 were analyzed by multivariate logistic
regression analysis [Odds ratio with 95% confidence
intervals (CI)] and the multivariate analyses were
conducted after including variables such as age, gender,
hemoglobin, serum albumin, calcium, phosphate and al-
kaline phosphatase. Statistical significance was accepted
if P<0.05. Data analysis was performed using SPSS for
Windows, version 12.0 (SPSS, Chicago, IL, USA).
Results
Subjects with CKD and estimated GFR of 34.19 ± 17.39
mL/min/1.73 m2 were screened for 25-hydroxyvitamin
D levels. The participants were all Thais, 52.4%, male,
38.6%, had type 2 diabetes and 64.4% had hypertension
as a comorbid disease. Table 1 shows the 2,895 subjects
grouped to investigate for differences in clinical and la-
boratory characteristics according to CKD status. The
values included age, gender, GFR, hemoglobin, serum
albumin, calcium, phosphorus, alkaline phosphatase
and intact-PTH differring among the CKD stages.
Notably, levels of 25-hydroxyvitamin D were signifi-
cantly lower according to severity of renal impairment
(CKD stage 3a: 27.84±14.03 ng/mL, CKD stage 3b:
25.86±11.14 ng/mL, CKD stage 4: 24.09±11.65 and
CKD stage 5: 20.82±9.86 ng/mL, p<0.001).
Of the 2,895 CKD patients, 72.7% had a diagnosis of
25-hydroxyvitamin D ≤ 30 ng/mL and 5.3% of 25-
hydroxyvitamin D deficiency defined as less than 10 ng/mL.
As shown in Figure 1, significant differences were ob-
served in stratified patients with 25-hydroxyvitamin D ≤
30 ng/mL according to the CKD stages (CKD stage 3a;
66.6%, CKD stage 3b; 70.9%, CKD stage 4; 74.6% and
CKD stage 5; 84.7%, p<0.001). An increasing prevalence of
vitamin D deficiency with increasing severity of CKD was
also found (Figure 1). Males, estimated GFR, serum al-
bumin, calcium and hemoglobin occurred significantly
less among patients with levels of 25-hydroxyvitamin D ≤
30 ng/mL. In contrast, patients with levels of 25-
hydroxyvitamin D ≤ 30 ng/mL presented significantly
increased serum phosphorus levels and intact-parathyroid
hormone levels (Table 2).
Table 3 shows the adjusted odds ratio for advanced
CKD stage in subjects categorized based on vitamin D
deficiency and insufficiency. Using multivariate logistic
regression analysis, an inverse association was observed
between serum 25-hydroxyvitamin D ≤ 30 ng/mL and
prevalent CKD stage 5 [adjusted odds ratio 2.19 (95% CI
1.07 to 4.48)] in the CKD population after adjusting for po-
tential confounders. Additionally, the association between









(N=581) (N=514) (N=838) (N=962)
Age (yr) 63.34±16.89* 71.29±12.77** 72.61±11.49* 68.83±12.2
Male (n, %) 286 (49.2%) 258 (50.2%) 479 (57.2%)** 493 (51.2%)
GFR (mL/min/1.73 m2) 7.64±3.34* 22.71±4.21* 38.17±4.3* 52.9±4.21
BUN (mg/dL) 49.27±18.25* 34.98±11.36* 23.39±6.75* 17.96±5.12
Serum creatinine (mg/dL) 7.34±3.27* 2.49±0.55* 1.6±0.25* 1.23±0.19
Hemoglobin (g/dL) 10.82±1.71* 11.07±1.57* 12±1.7* 12.56±1.63
Serum albumin (g/dL) 3.99±0.55* 4.08±0.49* 4.25±0.39** 4.33±0.42
Serum calcium (mg/dL) 9.3±1* 9.37±0.63* 9.51±0.64 9.56±0.56
Serum phosphorus (mg/dL) 4.53±1.43* 3.66±0.56* 3.46±0.56 3.37±0.56
Serum 25-hydroxyvitamin D (ng/mL) 20.82±9.86* 24.09±11.65* 25.86±11.14** 27.84±14.03
Serum alkaline phosphatase (U/L) 168.39±329.4* 91.33±50.15 78.11±57.81 71.82±32.15
Serum Intact-PTH (pg/mL) (interquartile ranges) 211.5* (102.2, 411.1) 83.5* (54.3, 124.4) 59.9b (42.5, 87.7) 51.8 (38.4, 77.1)
Data are mean ± SD and median with interquartile ranges; *P<0.01; **P<0.05 versus GFR 45–59 mL/min/1.73 m2.
Figure 1 Prevalence of vitamin D insufficiency and deficiency
by CKD category. Data are percentage; *P <0.001 versus GFR 45–59
mL/min/1.73 m2.
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CKD stage 5 [adjusted Odds ratio 16.76 (95% CI 4.89 to
57.49)] remained statistically significant in CKD partici-
pants, even after adjusting confounding factors.
Discussion
The principal finding of the present study is that vitamin
D insufficiency and deficiency are widely prevalent
among Thai CKD patients, similar to the general popu-
lation. Regardless of the geographic location in Thailand,
serum 25-hydroxyvitamin D level ≤30 ng/mL was
present in 66.6-84.7% of patients with stage 3a-5 CKD.
Also low vitamin D status has been reported among
Asian populations with normal kidney function despite
it being a tropical region [15-17]. This is the first epi-
demiological study in Asian tropical countries to use es-
timated GFR calculations to demonstrate that vitamin D
insufficiency and deficiency is associated with lower esti-
mated GFR.
Our findings complement recent observations suggesting
that vitamin D deficiency is strongly associated with
greater stages of CKD among adult participants. Among
14,679 US adult participants in the Third National Health
and Nutrition Examination Survey (NHANES III), mean
serum 25-hydroxyvitamin D level was lower in patients
with stage 4–5 CKD compared with those with normal
kidney function (24.6 vs. 29.3 ng/mL, P <0.001) [7]. Simi-
larly, another study measured serum 25-hydroxyvitamin D
levels in patients with CKD. The overall mean serum level
of 25-hydroxyvitamin D was 19 ±14 ng/mL and only 29%
of the 65 patients with stage 3 CKD and only 17% of
113 patients with stage 4 CKD had vitamin D insuffi-
ciency and deficiency [18]. Moreover, participants with25-hydroxyvitamin D levels <15 ng/mL had a 2.6-fold
greater incidence of ESRD than those with levels ≥15
ng/mL during a long-term follow-up [19]. In addition,
few studies demonstrated that low 25-hydroxyvitamin
D levels were independently associated with albumin-
uria in CKD and type 1 diabetes, but they did not find evi-
dence linking low concentrations of 25-hydroxyvitamin D
to early GFR loss [20,21]. Thus, current data and our find-
ing indicate that vitamin D deficiency/insufficiency is an
extremely frequent condition in patients with CKD, espe-
cially those with an estimated GFR of less than 15 mL/
min/1.73 m2.
Our results demonstrate a graded relationship between
serum 25-hydroxyvitamin D and the risk for kidney dis-
ease among subjects with CKD not undergoing dialysis.
A causal relationship has yet to be proved by interven-
tion trials using vitamin D. Several mechanisms might
explain the 25-hydroxyvitamin D deficiency in the CKD





>30 ng/mL ≤30 ng/mL
Age (yr) 70.19 ± 12.37 69.34 ± 13.59 0.271
Male (N, %) 239 (58.4%) 553 (50.7%) 0.008
GFR (mL/min/1.73 m2) 39.08 ± 15.83 33.22 ± 17.99 <0.001
BUN (mg/dL) 26.08 ± 13.15 30.84 ± 17.23 <0.001
Creatinine (mg/dL) 2.22 ± 2.09 2.99 ± 3.01 <0.001
Hemoglobin (g/dL) 11.84 ± 1.87 11.54 ± 1.72 0.025
Serum albumin (g/dL) 4.29 ± 0.48 4.14 ± 0.49 <0.001
Serum calcium (mg/dL) 9.53 ± 0.65 9.4 ± 0.74 0.009
Serum phosphorus (mg/dL) 3.56 ± 0.79 3.85 ± 1.08 <0.001
Serum alkaline
phosphatase (U/L)
79.75 ± 41.88 97.41 ± 95.91 0.052





Data are mean ± SD and median with interquartile ranges, P-value versus
serum 25-hydroxyvitamin D >30 ng/dL.
Table 3 Vitamin D insufficiency/deficiency associated
with advanced CKD stage defined as estimated GFR less
than 15 mL/min/1.73 m2 in the entire CKD subjects as












≤30 ng/dL 2.15 (1.56, 2.97) <0.001 2.19 (1.07, 4.48) 0.032
10-30 ng/dL 1.93 (1.39, 2.67) <0.001 1.84 (0.88, 3.82) 0.104
<10 ng/dL 8.72 (5.32, 14.29) <0.001 16.76 (4.89, 57.49) <0.001
>30 ng/dL Reference Reference
Multivariate analyses were done after including variables such as age, gender,
hemoglobin, serum albumin, calcium, phosphate and alkaline phosphatase.
P-value versus serum 25-hydroxyvitamin D >30 ng/dL (reference).
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stricted protein and caloric intake, so vitamin D is rela-
tively low [22]. Second, many CKD patients have limited
outdoor physical activities with reduced exposure to sun-
light [22]. Finally, greater loss of urinary vitamin D metab-
olites occurs in patients with overt proteinuria [23].
Increasing evidence supports that vitamin D metabol-
ism affects the risk of CKD, although the underlying mo-
lecular mechanism of this association remains hidden.
Mounting evidence from clinical studies has demon-
strated an inverse relationship between circulating vita-
min D levels and blood pressure and/or abnormalities of
the renin angiotensin-aldosterone system (RAAS). The
RAAS plays a key role in regulating blood pressure, vas-
cular remodeling and progressive kidney damage [24]. In
animal models, inhibiting 1,25(OH)(2)D synthesis led to
an increase in renin expression, whereas injecting 1,25
(OH)(2)D led to renin suppression [25]. Hence, 1,25
(OH)(2)D is a novel negative endocrine regulator of the
RAAS [26]. Moreover, replacement with pharmacologic
doses of vitamin D receptor agonists in animal models
of kidney disease consistently show reduced albumin-
uria, abrogated glomerulosclerosis, and glomerular in-
flammation [27,28]. Recently, a cohort study found that
serum 25-hydroxyvitamin D concentration was an inde-
pendent inverse predictor of disease progression and
death in patients with stages 2–5 CKD [3]. Collectively,
these data suggest a potential renoprotective effect of vita-
min D supplementation in patients with advanced CKD.
This study has several strengths including the large
number of participants, the complete nature of the
dataset and the ability to adjust to multiple CKD riskfactors. Despite the comprehensive nature of the dataset,
limitations occurred in the study. We enrolled only Thai
CKD patients in Bangkok, so caution is needed in gener-
alizing our finding with other populations. The CKD EPI
formula was not tested for accuracy in Thai population
and thus may be used for relative measurements of GFR
and comparisons between vitamin D deficiency and
non-vitamin D deficiency. Finally, our selection of sub-
jects might have been biased. Our participants were
mainly in the tertiary care center. This might be one rea-
son why more aging and chronically ill subjects
participated.
Conclusion
In summary, the present data indicate a high prevalence of
25-hydroxyvitamin D deficiency and insufficiency in Thai
patients with moderate and severe CKD not on dialysis.
Even though Thailand is in a tropical region, most patients
had suboptimal levels of serum vitamin D. Especially
among advanced stage CKD patients, 25-hydroxyvitamin
D deficiency is strongly and independently associated with
CKD. The results of our study raise an important public
health issue and needs to be confirmed by large-scale and
cohort studies in other populations.
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